menu
    • menu
    [{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LP-003","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LP-003","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"LP-003","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longbio Pharma \/ Qiming Venture Partners","highestDevelopmentStatusID":"14","companyTruncated":"Longbio Pharma \/ Qiming Venture Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Longbio Pharma

    Menu

    Longbio Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Longbio Pharma

                            China arrow
                            SupplySide West 2024
                            Not Confirmed

                            Longbio Pharma

                            China arrow
                            SupplySide West 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LP-003

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Qiming Venture Partners

                            Deal Size : $1.4 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            LongBio Announced the Completion of Series B2 Financing, Led by Qiming Venture Partners

                            Details : The financing aims to advance the clinical development of the company's lead product LP-003, a best-in-class, anti-IgE antibody, which is being evaluated for Chronic Spontaneous Urticaria.

                            Brand Name : LP-003

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 24, 2024

                            Lead Product(s) : LP-003

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Qiming Venture Partners

                            Deal Size : $1.4 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Longbio Pharma

                            China arrow
                            SupplySide West 2024
                            Not Confirmed

                            Longbio Pharma

                            China arrow
                            SupplySide West 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LP-003

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD

                            Details : LP-003 is a novel humanized monoclonal anti-IgE antibody candidate, which is being evaluated for the treatment of patients with chronic spontaneous urticaria.

                            Brand Name : LP-003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 12, 2024

                            Lead Product(s) : LP-003

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Longbio Pharma

                            China arrow
                            SupplySide West 2024
                            Not Confirmed

                            Longbio Pharma

                            China arrow
                            SupplySide West 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LP-003

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

                            Details : LP-003 is a novel monoclonal anti-IgE antibody, which is currently being evaluated for the treatment of adults with moderate-to-severe chronic spontaneous urticaria.

                            Brand Name : LP-003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 25, 2024

                            Lead Product(s) : LP-003

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth